<DOC>
	<DOCNO>NCT02438787</DOCNO>
	<brief_summary>The purpose study assess efficacy ustekinumab , adult anti-TNF ( alpha ) refractory participant active radiographic axial spondyloarthritis ( AxSpA ) , measure reduction sign symptom radiographic AxSpA .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Ustekinumab Treatment Anti-TNF ( Alpha ) Refractory Participants With Active Radiographic Axial Spondyloarthritis</brief_title>
	<detailed_description>This Phase 3 , multicenter ( one hospital medical school team work medical research study ) , randomize ( study medication assign participant chance ) , double-blind ( neither researcher participant know treatment participant receiving ) , placebo-controlled ( inactive substance ; pretend treatment [ drug ] compare clinical trial drug test drug real effect ) study . The study consist 3 phase ; Screening ( 8 week ) , Treatment phase : placebo-controlled ( Week 0 24 ) active treatment ( Week 24 Week 52 ) , Safety Follow-up ( 12 week ) . Participants randomly assign 1 3 treatment group : placebo , ustekinumab 45 mg ustekinumab 90 mg . The total duration study 64 week . Participants primarily assess Assessment SpondyloArthritis International Society ( ASAS ) 40 response Week 24 . Participants ' safety monitor throughout trial .</detailed_description>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants must diagnosis definite ankylose spondylitis ( AS ) , define modified 1984 New York criterion . The radiographic criterion must confirm central xray reader least 1 clinical criterion must meet Participants must symptoms active disease screen baseline , evidence Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score great equal ( &gt; =4 ) visual analog scale ( VAS ) score total back pain &gt; =4 , scale 0 10 Participants elevate high sensitivity Creactive protein ( hsCRP ) level &gt; =0.300 milligram per deciliter ( mg/dL ) screen Refractory either lack benefit document intolerance 1 1 antiTNF ( alpha ) agent Inadequate response least 2 nonsteroidal antiinflammatory drug ( NSAIDs ) 4week period total maximal dos NSAID ( ) , unable receive full 4 week maximal NSAID therapy intolerance , toxicity , contraindication NSAIDs . Participants complete ankylosis spine permit included study , limit approximately 10 percent ( % ) study population Participants inflammatory disease might confound evaluation benefit ustekinumab therapy , include limited , rheumatoid arthritis , systemic lupus erythematosus , Lyme disease Participants receive infliximab infliximab biosimilar , within 12 week first study agent administration ; receive adalimumab , adalimumab biosimilar , certolizumab pegol within 6 week first study agent administration ; receive etanercept etanercept biosimilar within 6 week first study agent administration Participants ever receive golimumab Participants pregnant , nursing , plan pregnancy father child enrol study within 5 month receive last administration study agent Participants receive systemic immunosuppressive diseasemodifying antirheumatic drug ( DMARDs ) methotrexate ( MTX ) , sulfasalazine ( SSZ ) , hydroxychloroquine ( HCQ ) within 4 week prior first administration study agent . Medications category include , limited leflunomide , chloroquine , azathioprine , cyclosporine , mycophenolate mofetil , gold , penicillamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>Golimumab</keyword>
	<keyword>STELARA</keyword>
</DOC>